文献速递临床试验与 GCP流行病学与生物统计

改善逾期异常癌症筛查结果随访的多层次基层医疗干预:一项集群随机临床试验

A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该务实性集群随机临床试验在美国3个医疗网络44家基层诊所纳入11980例至少1项异常癌症筛查结果未随访的患者,按1:1:1:1随机分为常规护理、电子健康记录提醒、提醒+外展、提醒+外展+导航四组。主要结局为入组后120天内完成推荐随访,提醒+外展+导航组校正比例为31.4%,常规护理组为22.9%,校正绝对差8.5%(95%CI 4.8%-12.0%,P<.001)。

要点

  • 提醒+外展+导航组120天内完成随访的校正比例为31.4%,常规护理组为22.9%,校正绝对差8.5%(95%CI 4.8%-12.0%,P<.001)。
  • 提醒+外展组120天内完成随访的校正比例为31.0%,提醒组为22.7%。
  • 240天随访完成率及按癌症类型和风险等级的亚组结果与主要结局相似。

核心结论

  • 包含电子健康记录提醒和患者外展(联合或不联合患者导航)的多层次基层医疗干预改善了乳腺癌、宫颈癌、结直肠癌和肺癌逾期异常筛查结果的及时随访。

研究设计与样本

  • 务实性集群随机临床试验,在美国3个医疗网络44家基层诊所开展,纳入2020年8月24日至2021年12月13日期间至少1项异常癌症筛查结果尚未随访的患者。
  • 患者、医生和诊所对治疗分组均未设盲。
  • 共纳入11980例患者,中位年龄60岁(IQR 52-69岁),女性64.8%,白人83.3%,15.4%通过医疗补助保险参保。

主要发现

  • 120天内完成推荐随访的校正比例:电子健康记录提醒+外展+导航组(n=3455)为31.4%,电子健康记录提醒+外展组(n=2569)为31.0%,电子健康记录提醒组(n=3254)为22.7%,常规护理组(n=2702)为22.9%。
  • 电子健康记录提醒+外展+导航组与常规护理组比较的校正绝对差为8.5%(95%CI 4.8%-12.0%,P<.001)。
  • 240天内完成推荐随访的次要结局及按癌症类型和异常筛查结果风险等级的亚组结果与主要结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Realizing the benefits of cancer screening requires testing of eligible individuals and processes to ensure follow-up of abnormal results. OBJECTIVE: To test interventions to improve timely follow-up of overdue abnormal breast, cervical, colorectal, and lung cancer screening results. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, cluster randomized clinical trial conducted at 44 primary care practices within 3 health networks in the US enrolling patients with at least 1 abnormal cancer screening test result not yet followed up between August 24, 2020, and December 13, 2021. INTERVENTION: Automated algorithms developed using data from electronic health records (EHRs) recommended follow-up actions and times for abnormal screening results. Primary care practices were randomized in a 1:1:1:1 ratio to (1) usual care, (2) EHR reminders, (3) EHR reminders and outreach (a patient letter was sent at week 2 and a phone call at week 4), or (4) EHR reminders, outreach, and navigation (a patient letter was sent at week 2 and a navigator outreach phone call at week 4). Patients, physicians, and practices were unblinded to treatment assignment. MAIN OUTCOMES AND MEASURES: The primary outcome was completion of recommended follow-up within 120 days of study enrollment. The secondary outcomes included completion of recommended follow-up within 240 days of enrollment and completion of recommended follow-up within 120 days and 240 days for specific cancer types and levels of risk. RESULTS: Among 11 980 patients (median age, 60 years [IQR, 52-69 years]; 64.8% were women; 83.3% were White; and 15.4% were insured through Medicaid) with an abnormal cancer screening test result for colorectal cancer (8245 patients [69%]), cervical cancer (2596 patients [22%]), breast cancer (1005 patients [8%]), or lung cancer (134 patients [1%]) and abnormal test results categorized as low risk (6082 patients [51%]), medium risk (3712 patients [31%]), or high risk (2186 patients [18%]), the adjusted proportion who completed recommended follow-up within 120 days was 31.4% in the EHR reminders, outreach, and navigation group (n = 3455), 31.0% in the EHR reminders and outreach group (n = 2569), 22.7% in the EHR reminders group (n = 3254), and 22.9% in the usual care group (n = 2702) (adjusted absolute difference for comparison of EHR reminders, outreach, and navigation group vs usual care, 8.5% [95% CI, 4.8%-12.0%], P < .001). The secondary outcomes showed similar results for completion of recommended follow-up within 240 days and by subgroups for cancer type and level of risk for the abnormal screening result. CONCLUSIONS AND RELEVANCE: A multilevel primary care intervention that included EHR reminders and patient outreach with or without patient navigation improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03979495.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Atlas SJ, Tosteson ANA, Wright A, et al. A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial. JAMA. 2023. PMID: 37815566. doi:10.1001/jama.2023.18755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。